CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk

Pharmacogenomics

Volumn 11, Issue 7, 2010, Pages 919-925

  Gervasini, Guillermo ^a   De Murillo, Silvia Gonzalez ^a   Ladero, Jose M ^b   Agndez, Jose Ag ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

colorectal cancer; CYP2W1; olymorphisms; pharmacogenetics; SNP

Indexed keywords

ALANINE; CYTOCHROME P450; CYTOCHROME P450 2W1; ISOLEUCINE; THREONINE; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; AMINO ACID SUBSTITUTION; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; THREONINE;

EID: 77954360555     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.66     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Pittman AM, Webb E, Carvajal-Carmona L et al.: Refnement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal cancer. Hum. Mol. Genet. 17(23), 3720-3727 (2008).
3. Tomlinson IP, Webb E, Carvajal-Carmona L et al.: A genome-wide association study identifes colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat. Genet. 40(5), 623-630 (2008). (Pubitemid 351601204)
4. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA: Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br. J. Cancer 87(6), 681-686 (2002).
5. Sinha R, Peters U, Cross AJ et al.: Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res. 65(17), 8034-8041 (2005).
6. Sachse C, Smith G, Wilkie MJ et al.: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23(11), 1839-1849 (2002).
7. Martinez C, Garcia-Martin E, Ladero JM et al.: Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 22(8), 1323-1326 (2001).
8. Agundez JA: Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. 5(3), 211-224 (2004).
9. Agundez JA: Polymorphisms of human N-acetyltransferases and cancer risk. Curr. Drug Metab. 9(6), 520-531 (2008).
10. Girault I, Rougier N, Chesne C et al.: Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 33(12), 1803-1810 (2005).
11. Aung PP, Oue N, Mitani Y et al.: Systematic search for gastric cancer-specifc genes based on sage data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25(17), 2546-2557 (2006).
12. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB: Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch. Biochem. Biophys. 436(1), 50-61 (2005).
13. Karlgren M, Gomez A, Stark K et al.: Tumor-specifc expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 341(2), 451-458 (2006).
14. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, Ingelman-Sundberg M: Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8(10), 1315-1325 (2007).
15. Edler D, Stenstedt K, Ohrling K et al.: The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer-a pilot study. Eur. J. Cancer 45(4), 705-712 (2009).
16. Wu Zl, Sohl CD, Shimada T, Guengerich FP: Recombinant enzymes overexpressed in bacteria show broad catalytic specifcity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol. Pharmacol. 69(6), 2007-2014 (2006).
17. Yoshioka H, Kasai N, Ikushiro S et al.: Enzymatic properties of human CYP2W1 expressed in Escherichia coli. Biochem. Biophys. Res. Commun. 345(1), 169-174 (2006).
18. Hanzawa Y, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M: Genetic polymorphisms and haplotype structures of the human CYP2W1 gene in a Japanese population. Drug Metab. Dispos. 36(2), 349-352 (2008).
19. Agundez JAG, Lozano L, Ladero JM et al.: N-acetyltransferase 2 (NAT2) genotype and colorectal carcinoma: risk variability according to tumour site? Scand. J. Gastroenterol. 35(10), 1087-1091 (2000).
20. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J: Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther. Drug Monit. 27(6), 819-821 (2005).
21. Martinez C, Martin F, Fernandez JM et al.: Glutathione S-transferases μ 1, q1, p1, a1 and μ 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. Pharmacogenomics 7(5), 711-718 (2006).
22. Agundez JA, Golka K, Martinez C, Selinski S, Blaszkewicz M, Garcia-Martin E: Unraveling ambiguous NAT2 genotyping data. Clin. Chem. 54(8), 1390-1394 (2008).
23. Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003).
24. Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 23(3), 381-387 (2002).
25. Agundez JA, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J: Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin. Pharmacol. Ther. 55(4), 412-417 (1994).
26. Adams SM, Bosch E, Balaresque PL et al.: The genetic legacy of religious diversity and intolerance: paternal lineages of Christians, Jews, and Muslims in the Iberian peninsula. Am. J. Hum. Genet. 83(6), 725-736 (2008).
27. Lucotte G, Gerard N, Mercier G: North African genes in Iberia studied by y-chromosome DNA haplotype 5. Hum. Biol. 73(5), 763-769 (2001). (Pubitemid 33145721)
28. Li W, Tang Y, Hoshino T, Neya S: Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates. J. Mol. Graph. Model. 28(2), 170-176 (2009).
29. Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30(17), 3894-3900 (2002).
30. Martinez C, Galvan S, Garcia-Martin E, Ramos MI, Gutierrez-Martin Y, Agundez JA: Variability in ethanol biodisposition in whites is modulated by polymorphisms in the ADH1B and ADH1C genes. Hepatology 51(2), 491-500 (2010).
31. Ingelman-Sundberg M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25(4), 193-200 (2004).
32. Karlgren M, Ingelman-Sundberg M: Tumour-specifc expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin. Ther. Targets 11(1), 61-67 (2007).